drugset / Trial / NCT02233023

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

NCT02233023

Phase 4 Completed 705 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Study to assess and compare the safety of long term oral treatment for Parkinson's Disease with pramipexole versus bromocriptine or other dopamine agonists, by measuring cross-sectional the incidence of ophthalmologic disturbances, especially signs of retinal degeneration, in a matched pair design

Timeline

Start
1998-06
Primary completion
2000-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bromocriptine Small molecule Oral
Subject Pramipexole Unknown Oral

Indications